Mahana Therapeutics Selected for Prestigious Digitalhealth.London Accelerator Program | Your money


Mahana Therapeutics, a leading developer of digital prescription therapies designed to empower people with chronic conditions, today announced that Mahana has been selected for the Accelerator program at DigitalHealth.London.

This press release is multimedia. View the full press release here:

Mahana IBS is a digital therapy that offers cognitive behavioral therapy to help adults with irritable bowel syndrome reduce the severity of symptoms. (Graphic: Mahana Therapeutics)

The Accelerator 2022 program selects companies offering high-potential digital solutions or services to meet the challenges of the National Health Service (NHS) and social services in London. Mahana IBS offers cognitive behavioral therapy (CBT) to help adults with irritable bowel syndrome (IBS) reduce the severity of symptoms. In the UK, up to 10% of the population is affected by IBS and the disease costs the NHS over £200 million a year.

Now in its sixth consecutive year, the NHS-implemented programme, which is co-funded by the European Regional Development Fund, has supported some of the most effective digital innovations currently in use by the NHS. The program will help Mahana Therapeutics better collaborate with the NHS to accelerate the adoption of Mahana IBS into clinical practice. Mahana IBS has the potential to deliver significant cost savings to the NHS and provide a new way to treat IBS for millions affected.

This year, the companies on the program will benefit from international partnerships with two American accelerators, Cedars-Sinai and Mass Challenge. Partnerships with these US-based accelerators will provide companies like Mahana the opportunity to network with global peers, showcase their products/services to key international stakeholders, and gain the tools to navigate a new global market.

Jenny Thomas, Program Director, DigitalHealth.London, said, “We are delighted to announce today that 21 digital health companies are joining our sixth DigitalHealth.London Accelerator cohort. The application process for this year’s program was more competitive than ever, and as such, the final 21 companies are truly the ones to watch in the digital health space. We look forward to working with them and continuing to play our part in supporting the NHS and social services through digital transformation. »

Jon Scholefield, managing director of Mahana UK Operations, said: “Mahana Therapeutics is committed to helping people with IBS and other chronic conditions digitally access effective cognitive behavioral therapy. We are excited to join this prestigious program to accelerate the adoption and experience of Mahana IBS within the NHS. We look forward to bringing this valuable new treatment option into clinical practice for people living with IBS.”

Sonia Patel, Chief Information Officer, NHSX, said: “The DigitalHealth.London Accelerator program has established itself as an important player in supporting the NHS and social services to make the most of the opportunities offered by digital health. I can’t wait to see the next group of innovators bring their solutions to London’s NHS.

DigitalHealth.London’s accelerator aims to accelerate the adoption of technology in London’s NHS, relieving severe pressure on services and empowering patients to manage their health. For every £1 spent on the program through the AHSNs, £12.70 is saved for the NHS*. He works with around 20 high-potential SMEs over a 12-month period, offering tailored support and advice, a program of expert-led workshops and events, and brokering meaningful connections between innovators and organizations. of the NHS with specific challenges. Companies that have successfully entered the Accelerator program have been chosen following a rigorous and highly competitive selection process, involving assessments from NHS experts and industry panels, interviews and background checks. due diligence.

For more information on companies participating in the program, visit:

About Mahana Therapeutics

Mahana Therapeutics is a leading developer of effective prescription digital therapies designed to enable patients with chronic conditions to live more fulfilling lives. The company’s first product, Mahana IBS, is the world’s first digital therapy to receive FDA clearance and CE Mark for the treatment of IBS and provides gut-directed cognitive behavioral therapy (CBT) to patients. adults with IBS. More information is available at

About DigitalHealth.London Accelerator

The DigitalHealth.London Accelerator was DigitalHealth.London’s first program. It is aimed at digital health companies who would benefit from better engagement with the NHS and the wider health sector, to refine and develop products and services that meet the needs of the system.

The DigitalHealth.London Accelerator is run by a consortium of founding partners including two of London’s Academic Health Sciences Networks (AHSN) – the Health Innovation Network and UCLPartners – along with CW+ and MedCity. The program is partly funded by the European Regional Development Fund (ERDF) under the European Structural and Investment Funds Growth Programme.

*DigitalHealth.London Accelerator Interim Evaluation report available for download here:—Interim-Report—v1-2.pdf

Cedars-Sinai Accelerator:

Mass Challenge partnership announcement:

About the European Regional Development Fund

The project is receiving up to £3.8 million in funding from England’s European Regional Development Fund under the European Structural and Investment Funds Growth Program 2014-2020. The Department of Housing, Communities and Local Government (and in London the intermediary body Greater London Authority) is the managing authority for the European Regional Development Fund. Created by the European Union, the European Regional Development Fund helps local areas boost their economic development by investing in projects that will support innovation, businesses, job creation and the local community.

For more information, visit

See the source version on

CONTACT: Mahana Therapeutics Media ContactMichele Parisi



[email protected]



SOURCE: Mahana Therapeutics

Copyright BusinessWire 2022.

PUBLISHED: 01/18/2022 04:05 AM/DISC: 01/18/2022 04:06 AM

Copyright BusinessWire 2022.

Ryan H. Bowman